Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer

Northside Hospital, Inc.

Status and phase: Completed; Phase 2

Conditions: Lymphoma; Leukemia; Myelodysplastic Syndromes

Treatments: Drug: busulfan; Drug: fludarabine phosphate; Procedure: allogeneic hematopoietic stem cell transplantation; Drug: cyclophosphamide; Procedure: peripheral blood stem cell transplantation; Drug: tacrolimus; Drug: mycophenolate mofetil

Study type: Interventional

Funder types: Other

Identifiers

NCT00782379

BMTGG-NSH-864

CDR0000617648

Details and patient eligibility

About

RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and cyclophosphamide, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving high-dose cyclophosphamide together with tacrolimus and mycophenolate mofetil after transplant may stop this from happening.

PURPOSE: This phase II trial is studying how well combination chemotherapy works when given together with a donor stem cell transplant, followed by tacrolimus, mycophenolate mofetil, and high-dose cyclophosphamide, in treating patients with high-risk hematologic cancer.

Full description

OBJECTIVES:

Primary

• To estimate the incidence of graft rejection and severe graft-versus-host disease after myeloablative HLA-mismatched peripheral blood stem cell transplantation (PBSCT) from first-degree relatives in patients with high-risk hematologic malignancies.

Secondary

• To estimate overall survival, relapse, non-relapse mortality, and event-free survival in these patients.
• To characterize additional hematologic and non-hematologic toxicities of myeloablative haploidentical PBSCT.
• To characterize donor hematopoietic chimerism in peripheral blood stem cells after PBSCT.

OUTLINE:

• Preparative regimen: Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -2, busulfan IV over 3 hours on days -7 to -4, and cyclophosphamide IV over 1-2 hours on days -3 and -2.
• Allogeneic peripheral blood stem cell transplantation (PBSCT): Patients undergo infusion of unmanipulated peripheral blood stem cells on day 0.
• Post-transplant regimen: Patients receive high-dose cyclophosphamide IV over 1-2 hours on days 3 and 4, tacrolimus IV over 24 hours or orally twice daily on days 5-180, and oral mycophenolate mofetil 3 times daily on days 5-34 followed by a taper to day 90. Treatment continues in the absence of disease progression or clinically significant graft-vs-host disease.

After completion of PBSCT, patients are followed periodically for 1 year.

Enrollment: 20 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

• Diagnosis of one of the following high-risk hematologic malignancies:

  • Chronic myelogenous leukemia meeting one of the following criteria:

    • Disease in chronic phase and resistant to available tyrosine kinase inhibitors
    • Disease in accelerated phase
    • Disease with blast crisis that has entered into a second chronic phase after induction chemotherapy

  • Acute myelogenous leukemia meeting the following criteria:

    • Marrow blasts < 5% but persistence of minimal residual disease by flow cytometry, cytogenetics, or FISH

    • Must meet one of the following criteria:

      • Disease in second or subsequent complete remission
      • Primary induction chemotherapy failure with disease subsequently entering complete remission
      • Disease in first complete remission with poor-risk cytogenetics or arising from preceding hematological disease

  • Myelodysplastic syndrome meeting at least one of the following criteria:

    • Treatment-related
    • Monosomy 7 or complex cytogenetics
    • International prognostic scoring system score ≥ 1.5
    • Chronic myelomonocytic leukemia

  • Acute lymphocytic leukemia or lymphoblastic lymphoma meeting the following criteria:

    • Marrow blasts < 5% but persistence of minimal residual disease by flow cytometry, cytogenetics, or FISH

    • Must meet one of the following criteria:

      • Disease in second or subsequent complete remission
      • Acute lymphocytic leukemia with poor-risk karyotype [e.g., t(9;22) or bcr-abl fusion, t(4;11), or other MLL translocation] and in first complete remission

  • Chronic lymphocytic leukemia or prolymphocytic leukemia meeting both of the following criteria:

    • Previously treated disease that has either relapsed or failed to respond adequately to conventional-dose therapy including purine analogs
    • In the opinion of the transplant physician, unlikely to benefit from reduced intensity transplantation due to the presence of one or more high-risk features (i.e., bulky tumor masses, B symptoms, and/or inadequate response to salvage chemotherapy)

  • Hodgkin or non-Hodgkin lymphoma (including low-grade, mantle cell, and intermediate-grade/diffuse disease) meeting the following criteria:

    • Previously treated disease that has either relapsed or failed to respond adequately to conventional-dose therapy or autologous transplantation
    • In the opinion of the transplant physician, unlikely to benefit from reduced intensity transplantation due to the presence of one or more high-risk features (i.e., bulky tumor masses, B symptoms, and/or inadequate response to salvage chemotherapy) NOTE: A new classification scheme for adult non-Hodgkin lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.

• No available matched related or unrelated donor OR a matched related or unrelated donor will not be available in the time frame necessary to perform a transplant

• Availability of a first-degree relative (parent, child, sibling) matched at 3/6-5/6 loci (HLA-A, -B, -DR)

  • Donor must be willing to donate mobilized peripheral blood stem cells
  • No positive HLA crossmatch in the host-vs-graft direction or high titer donor-specific antibodies

PATIENT CHARACTERISTICS:

• Karnofsky performance status 70-100%
• Bilirubin < 2 mg/dL (unless due to hemolysis, Gilbert syndrome, or primary malignancy)
• Creatinine < 2 mg/dL OR creatinine clearance ≥ 40 mL/min
• Not pregnant
• Fertile patients must use effective contraception
• LVEF (Left ventriculr ejection fraction) ≥ 45%
• FEV_1 and forced vital capacity ≥ 50% predicted
• No HIV positivity
• No debilitating medical or psychiatric illness that would preclude giving informed consent or receiving optimal treatment and follow-up

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• No immunosuppressive agents ≤ 24 hours after completion of post-transplant cyclophosphamide (including steroids as antiemetics)

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

Myeloablative Haploidentical Transplant

Experimental group

Description:

All patients will receive treatment using Fludarabine, Busulfan and Cyclophosphamide prior to receiving a haploidentical transplant followed by post-transplant cyclosphosphamide.

Treatment:

Drug: tacrolimus

Drug: mycophenolate mofetil

Procedure: peripheral blood stem cell transplantation

Drug: cyclophosphamide

Drug: busulfan

Procedure: allogeneic hematopoietic stem cell transplantation

Drug: fludarabine phosphate